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AbstrAct
Background Reduced ventilatory function is an 
established predictor of all-cause mortality in general 
population cohorts. We sought to verify this in lifelong non-
smokers, among whom confounding by active smoking 
can be excluded, and investigate associations with 
circulatory and cancer deaths.
Methods In UK Biobank, among 149 343 white never-
smokers aged 40–69 years at entry, 2401 deaths occurred 
over a mean of 6.5-year follow-up. In the Health Surveys 
for England (HSE) 1995, 1996, 2001 and Scottish Health 
Surveys (SHS) 1998 and 2003 combined, there were 500 
deaths among 6579 white never-smokers aged 40–69 
years at entry, followed for a mean of 13.9 years. SD (z) 
scores for forced expiratory volume in the first second 
(FEV1) and forced vital capacity (FVC) were derived 
using Global Lung Initiative 2012 reference equations. 
These z-scores were related to deaths from all causes, 
circulatory disease and cancers using proportional hazards 
models adjusted for age, sex, height, socioeconomic 
status, region and survey.
Results In the HSE–SHS data set, decreasing z-scores for 
FEV1 (zFEV1) and FVC (zFVC) were each associated to a 
similar degree with increased all-cause mortality (hazard 
ratios per unit decrement 1.17, 95% CI 1.09 to 1.25 for 
zFEV1 and 1.19, 95% CI 1.10 to 1.28 for zFVC). This was 
replicated in Biobank (HRs 1.21, 95% CI 1.17 to 1.26 and 
1.24, 1.19 to 1.29, respectively). zFEV1 and zFVC were 
less strongly associated with mortality from circulatory 
diseases in HSE–SHS (HR 1.22, 95% CI 1.06 to 1.40 for 
zFVC) than in Biobank (HR 1.47, 95% CI 1.35 to 1.60 for 
zFVC). For cancer mortality, HRs were more consistent 
between cohorts (for zFVC: HRs 1.12, 95% CI 1.01 to 
1.24 in HSE–SHS and 1.10, 1.05 to 1.15 in Biobank). The 
strongest associations were with respiratory mortality (for 
zFVC: HRs 1.61, 95% CI 1.25 to 2.08 in HSE–SHS and 
2.15, 1.77 to 2.61 in Biobank).
Conclusions Spirometric indices predicted mortality more 
strongly than systolic blood pressure or body mass index, 
emphasising the importance of promoting lung health in 
the general population, even among lifelong non-smokers.
IntroductIon
Four decades of epidemiological research 
have consistently shown that reduced levels of 
ventilatory function, measured as one-second 
forced expiratory volume (FEV1) or forced 
vital capacity (FVC), are associated with 
higher all-cause mortality rates, and therefore 
shorter survival in the general population.1–7 
Few studies have reported specifically on life-
long non-smokers,3 4 a group which form the 
minority of most populations surveyed hith-
erto, but are set to become more common in 
future as smoking becomes less prevalent in 
higher income countries.
Most publications have focused on FEV1, 
but a recent analysis7 of asymptomatic partic-
ipants in the multiethnic Atherosclerosis Risk 
in Communities (ARIC) Study reported that 
all-cause mortality was strongly associated 
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Strengths and limitations of this study
 ► UK Biobank offers a spirometric study of lifelong 
non-smokers of unprecedented size, but the low 
participation rate may have compromised its 
generalisability.
 ► Assembling data from five national health surveys 
of England or Scotland produced a cohort of never-
smokers, larger than in previously published studies, 
in which the generalisability of Biobank results could 
be tested.
 ► Within Biobank, the large numbers permitted 
statistically powerful  subgroup analyses by sex, 
age, obesity  and pre-existing disease. These 
within-cohort comparisons provide further 
reassurance  about generalisability of associations 
between reduced ventilatory function and mortality.
 ► Mortality associations among the subset of Biobank 
participants whose spirograms met internationally 
recommended criteria for acceptability and 
reproducibility were very similar to the results 
among the full Biobank cohort, suggesting that the 
key findings are robust to inclusion or exclusion of 
participants with suboptimal spirometry.
 ► In common with previous studies of this issue, 
this analysis was restricted to fatal outcomes and 
therefore cannot distinguish between an association 
of reduced ventilatory function with disease 
incidence and an influence on case-fatality.
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with diminished FVC, after adjustment for FEV1, but 
not the other way around, and there was no association 
between survival and the ratio of FEV1 to FVC. This 
conclusion was based on a combined analysis of smokers 
and non-smokers.
In this report, we compare the relationship of lung 
function measures (FEV1 and FVC) with subsequent 
mortality in UK Biobank (UKB) and in the Health Surveys 
for England (HSE) and Scottish Health Surveys (SHS). 
Biobank is the largest spirometric study ever performed 
in the UK and included a relatively high proportion of 
never-smokers. The national health surveys, although 
based on smaller numbers of subjects, recruited a wider 
age range, have a longer period of follow-up, higher 
response rates and are more representative of the 
general UK population than Biobank. The two sources 
are therefore complementary, in terms of precision and 
generalisability.
This paper focuses on findings for white lifelong 
non-smokers, among whom confounding by frequency or 
duration of active smoking can be excluded. We investi-
gate associations of spirometric indices with total mortality 
and with major groups of causes of death, compare FEV1 
and FVC as independent predictors of all-cause mortality 
and evaluate the possibility of reverse causation. We also 
compare results from UKB with those from the national 
health survey participants of a similar age at spirometric 
examination, to establish how widely generalisable are 
the findings from Biobank. Corresponding results for 
white former smokers and current smokers are included 
in the online supplement for completeness and described 
briefly in the text.
Methods
hse and shs
Data were combined from the HSE 1995, 1996 and 
20018–10 and the SHS 1998 and 2003,11–12 the years when 
spirometry was included in the protocol. These surveys 
aimed to recruit a representative sample of British adults 
through household sampling within selected parliamen-
tary constituencies throughout England or Scotland. 
Participants were visited at home. Response rates ranged 
from 60% to 76% across the five surveys. The proportion 
of those visited who performed usable spirometry ranged 
from 63% to 84%.
Spirometry was performed using handheld pneumota-
chograph spirometers (Vitalograph Escort) with the best 
results of FEV1 and FVC recorded from three technically 
satisfactory blows. No flow-volume curves or reproduc-
ibility criteria were available for assessment. Valid lung 
function measurements were available for 6579 lifelong 
non-smokers aged 40–69 years and 1429 aged 70 years or 
more at the start of follow-up, all of white ethnicity.
Deaths occurring up to April 2013 were available for 
analysis in the HSE,13 and deaths up to December 2011 
were linked in the SHS.14 Combining all five surveys, 
there were 500 deaths among white never-smokers aged 
40–69 years at recruitment over a mean follow-up period 
of 13.9 years. Deaths from respiratory disease, circulatory 
disease, cancer and all other causes were coded using 
International Classification of Diseases (ICD9) (460–519, 
390–459, 140–208 and all others, respectively) and ICD10 
(chapters J, I, C and all others, respectively).
Smoking history was self reported. Socioeconomic 
status was measured at the level of the household, based 
on the social class of the head of the household. Nation 
(England or Scotland), region (within England) and 
survey year were included as additional covariates.
uK Biobank
This study recruited 502 682 volunteers aged 40–69 years 
in 22 recruitment centres throughout England, Wales 
and Scotland during 2006–2010, following invitations to 
9 million people.15 Spirometry was performed using a 
handheld pneumotachograph spirometer (Pneumotrac 
6800) from which volume–time arrays were stored for 
each blow.16
Eighty-one per cent of the cohort performed two blows 
with acceptable start and measures of FEV1 reproducible 
within 250 mL. This was considered the most inclusive 
sample of ‘usable spirograms’. When end-blow quality 
was also considered, 58% of the cohort had evidence of a 
good plateau and both FEV1 and FVC reproducible within 
150 mL, the criteria recommended by the American 
Thoracic Society/European Respiratory Society (ATS/
ERS) Task Force on Standardisation of Spirometry.17 
This subgroup of 58% was considered to be the ‘best 
quality’ spirograms, among which to evaluate the relative 
importance of FEV1 and FVC as predictors of mortality.
The present analysis is based on deaths occurring 
up to mid-August 2015, a mean follow-up period of 6.5 
years. There were 2401 deaths among 149 343 lifelong 
non-smokers aged 40–69 years of white ethnicity who 
performed ‘usable spirograms. Deaths from respiratory 
disease, circulatory disease, cancer and all other causes 
were coded using ICD10 (chapters J, I, C and all others, 
respectively).
Smoking history was self reported. Socioeconomic 
status was measured at the level of residential area, using 
the Townsend Deprivation Index, grouped into quartiles 
for analysis. Biobank recruitment centre was used as an 
additional covariate to adjust for possible regional differ-
ences.
Adjustment of spirometric measures for gender, age and 
height
The Global Lung Initiative (GLI) 2012 reference equations 
for white ethnic groups18 were used in both sets of data to 
standardise FEV1 and FVC for age, sex and height. The 
GLI-2012 equations generate a ‘z-score’ which represents 
the relative position of an individual among the distribu-
tion predicted for lifelong non-smokers with no history 
of lung disease of the same gender, age and height. This 
allows for the spread of predicted values to differ by age, 
height and gender, expressing the relative ranking of an 
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individual in terms of a SD (z) score. For each individual 
in the analysis, there were three GLI-2012 z-scores, corre-
sponding to their relative ranking for FEV1 (zFEV1), FVC 
(zFVC) and the ratio FEV1:FVC (zFEVFVC). Outlying 
observations were excluded by restricting all the analyses 
in both data sets to values of zFEV1 and zFVC within the 
range −5 to +5 z-score units. This exclusion removed 0.2% 
of UKB participants, 0.5% of participants in the national 
health surveys aged 40–69 years and 0.3% of national 
health survey participants aged 70 years or more.
Modelling of mortality
The relationship of spirometric indices with subsequent 
mortality was modelled by proportional hazards (Cox) 
regression, which estimates the relative increase in 
mortality rate (HR) for a unit change in each explanatory 
variable. The z-scores are expressed on a SD scale, so HRs 
for zFEV1 and zFVC are expressed per unit decrement 
(ie, an increase in risk for a decrease in lung function). 
A typical range of z-scores among lifelong non-smokers 
would be 4 units. A HR of 1.2 per unit decrement corre-
sponds approximately to a twofold difference in mortality 
rate across this range.
Due to the high correlation between zFEV1 and zFVC 
among lifelong non-smokers (0.88 in Biobank, 0.80 in 
national health survey participants aged 40–69 years), we 
modelled the association of mortality with zFEV1 both 
alone and jointly with zFEVFVC, and similarly for zFVC. 
Among never-smokers, the correlations between zFEV1 
and zFEVFVC (0.35 in Biobank, 0.36 in the national 
surveys) and between zFVC and zFEVFVC (−0.13 in 
Biobank, −0.20 in the national surveys) were weak enough 
to avoid major collinearity in the joint models. The signif-
icance of the HR for zFEVFVC when modelled jointly 
with zFEV1 was used to assess whether zFVC predicted 
mortality independent of zFEV1, and vice versa when 
zFEVFVC was modelled jointly with zFEV1.
All proportional hazards models were restricted to 
white participants and adjusted for sex, age, standing 
height, socioeconomic status and region. Analyses of 
data from the five national health surveys were addi-
tionally adjusted for survey year as a categorical variable. 
Since each survey was conducted in a different year, 
inclusion of survey year in the model is closely equivalent 
to a fixed-effect meta-analysis of the results from each of 
the five surveys. In a more formal two-stage individual 
participant meta-analysis for all-cause mortality in life-
long non-smokers, there was no substantial or significant 
heterogeneity of HRs among the five national health 
surveys (I²=0.0%, p=0.775 for zFEV1; I²=10.5%, p=0.346 
for zFVC). Therefore, for simplicity of presentation we 
report results for the five national surveys combined, 
but analyse UKB separately because one of our objec-
tives is to investigate how closely these two sets of results 
correspond. Heterogeneity between HRs for the pooled 
national surveys and UKB was assessed by testing the 
significance of the difference between the corresponding 
log-HRs from these two data sets.
The assumption of proportionality of hazards was 
assessed by log-log plots and by fitting zFEV1 or zFVC 
as a time-dependent covariate in the model. No strong 
or statistically significant evidence of time depen-
dence emerged for all-cause mortality among lifelong 
non-smokers. Nevertheless, results for all-cause mortality 
were partitioned at 5 years of follow-up for two reasons. 
First, because the minimum duration of follow-up in 
UKB was 4.87 years, so virtually all of that cohort had 
been followed for 5 years or more, allowing a more direct 
comparison with results from the national health surveys, 
all of which had been followed for more than 5 years. The 
second reason for partitioning at 5 years was to address 
the possibility of reverse causation (impaired spirometric 
performance due to pre-existing conditions which lead 
to early death). Reverse causation was also investigated by 
analysing mortality in subgroups with no prior history of 
respiratory disease, circulatory disease or cancer.
results
Participant characteristics
Online supplementary e-table 1 summarises the number 
of participants, duration of follow-up and deaths from all 
causes and subgroups of cause, in each data set, by sex, 
age and smoking history.
All-cause mortality
Table 1 compares the HRs for age–sex–height-adjusted 
FEV1 and FVC in relation to all-cause mortality in the 
combined HSE and SHS data set, and UKB, among 
participants aged 40–69 years at entry. All ‘usable spiro-
grams’ from Biobank were included in this comparison, 
because no additional quality control had been applied in 
the national health surveys 1995–2003.
When each spirometric index was modelled singly, 
all associations were highly statistically significant 
(p<0.0001). Among lifelong non-smokers in both cohorts, 
FEV1 and FVC displayed similar strengths of association 
with all-cause mortality (table 1). Among former smokers, 
FEV1 was the stronger predictor in HSE–SHS but FEV1 
and FVC showed similar strength of association with 
all-cause mortality in UKB. Among current smokers in 
both data sets, FEV1 was a stronger predictor of all-cause 
mortality than FVC (see online supplementary e-tables 
2–4).
Table 1 also shows the most direct comparison between 
the two data sets, based on all-cause mortality within 5 
years. Although the associations of spirometric indices 
with these earlier deaths were stronger in HSE–SHS than 
in UKB, the differences between the cohorts were not 
statistically significant (p=0.23 for FEV1, p=0.39 for FVC). 
Associations with deaths after 5 years are less compa-
rable between the data sets, due to the shorter period of 
follow-up in UKB.
Stronger associations of FEV1 and FVC with earlier 
deaths than with later mortality from all causes were also 
evident among former smokers and current smokers, 
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although the differences were more marked in HSE–SHS 
than in UKB (see online online supplementary e-tables 
1 and 3). Formal tests for time dependence of the HR 
for all-cause mortality found statistically significant reduc-
tion in HR with increasing follow-up time (t) only among 
ex-smokers (p=0.00032 for zFEV1*t in UKB, p=0.021 for 
zFEV1*t in HSE–SHS, p=0.000006 for zFVC*t in UKB, 
p=0.001 for zFVC*t in HSE–SHS). Among never-smokers 
and current smokers in both data sets, the reduction in 
HR with increasing follow-up was small (a relative reduc-
tion of 1% per year) and non-significant (p>0.05) for 
both FEV1 and FVC.
These analyses confirm that the modelling assump-
tion of proportionality of hazards over the duration of 
follow-up is valid, at least for lifelong non-smokers, in 
both data sets.
Influence of spirogram quality
Table 2 presents the results for all causes of death among 
Biobank participants with ‘best quality’ spirograms, 
for comparison with those obtained from the full set 
of ‘usable spirograms’. The pattern and magnitude of 
the results among the former subset are very similar to 
the overall UKB results. The covariate-adjusted HRs for 
all-cause mortality comparing the ‘best quality’ group to 
the remainder were: HR 0.94 (95% CI 0.86 to 1.02) among 
lifelong non-smokers, 1.02 (0.96 to 1.09) among former 
smokers and 0.94 (0.85 to 1.04) among current smokers. 
None of these HRs are statistically significant, despite very 
large number of subjects included each comparison.
choice of spirometric index
Among lifelong non-smokers, adding FEV1:FVC ratio 
to a model including FVC did not contribute addi-
tional information, whereas adding FEV1:FVC ratio to a 
model including FEV1 did improve the fit of the model 
significantly (table 2). This pattern was evident in both 
HSE–SHS and UKB, and among the subset of UKB partic-
ipants with ‘best quality’ spirograms.
cause-specific mortality
Table 1 also presents the association of spirometric 
indices (modelled singly) with respiratory, circula-
tory, cancer and other causes of death among lifelong 
non-smokers. The strength of association with FEV1 and 
FVC was greatest for respiratory mortality and weakest 
for cancer deaths. This applied in both data sets, but 
the HRs for respiratory, circulatory and other causes 
of death were greater in UKB than in HSE–SHS. The 
results in the two cohorts are more similar for cancer 
mortality. The heterogeneity of HRs between the two 
data sets was statistically significant only for FVC in 
relation to circulatory mortality (p=0.025), and for 
both FEV1 (p=0.009) and FVC (p=0.042) in relation 
to causes of death other than respiratory, circulatory 
or cancer among never-smokers. Within UKB, results 
for cause-specific mortality were generally consistent 
between the ‘best spirogram’ subgroup and the fuller 
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data set in all smoking subgroups (see online supple-
mentary e-table 4).
comparisons by subgroups of age and sex
Online supplementary e-table 3 shows that within UKB 
the general pattern of results was similar in both sexes. 
There was no statistically significant effect modification by 
sex for either spirometric index in any smoking subgroup 
(p>0.10 for each interaction test).
Online supplementary e-table 3 also compares the 
results for all-cause mortality among younger (aged 
40–59 years) and older (aged 60–69 years) UKB partic-
ipants. The HRs in all smoking groups were consistent 
between these two age subgroups and there were no 
statistically significant age interactions for either spiro-
metric index (p>0.40).
Online supplementary e-table 5 compares the spiro-
metric associations with all-cause and cause-specific 
mortality among HSE and SHS participants aged 40–69 
years and 70 years or more at entry. The pattern for 
all causes was consistent between these age groups in 
never-smokers and current smokers (p>0.2), but there 
were significant age interactions among ex-smokers 
(p<0.006).
Online supplementary e-table 3 compares the results 
for all-cause mortality among obese and non-obese 
Biobank participants. Although the pattern of results 
was generally consistent between these categories in all 
smoking subgroups, a statistically significant difference 
in the HR for FVC occurred among current smokers 
(p=0.022). Other interactions with obesity were non-sig-
nificant (p>0.10).
comparisons by prior disease history in uKB
Table 3 compares the spirometric associations with 
all-cause mortality in Biobank participants with and 
without a history of respiratory disease at the baseline 
spirometric examination. In the 18 545 (12%) white 
never-smokers with ‘usable spirograms’ who had a history 
of diagnosed respiratory disease (of which 90% reported 
asthma), FVC was a stronger predictor of all-cause 
mortality than FEV1. Among the subgroup without a 
respiratory history, results were similar to the full cohort.
Lung function also emerged as a significant predictor 
of circulatory mortality among those with and without a 
prior history of heart attack, angina, stroke, thrombosis or 
hypertension (table 3). This pattern was confirmed among 
former smokers and current smokers (see online supple-
mentary e-table 3).
Finally, the association of FEV1 and FVC with cancer 
mortality was shown to be stronger in those with a prior 
cancer diagnosis (table 3), but it was not statistically 
significant, despite the large sample size, among those 
with no cancer history at the spirometric examina-
tion. However, this finding is confined to the lifelong 
non-smokers: both FEV1 and FVC were more strongly and 
significantly associated with cancer death among former 
smokers and current smokers with no cancer history 
(see online supplementary e-table 6). Cancer mortality 
among participants with a history of cancer at entry was 
strongly and significantly associated with both FEV1 and 
FVC in all three smoking subgroups (see online supple-
mentary e-table 6).
comparison of spirometry with other predictors of mortality
Figure 1 (data in online supplementary e-table 7) 
compares the relative mortality across quartiles of body 
mass index, systolic blood pressure and FVC z-score, for 
all deaths and for deaths from circulatory disease, among 
white lifelong non-smokers in HSE–SHS and in UKB. A 
similar pattern emerged for all-cause mortality in both 
cohorts, with differentials in mortality across quartiles of 
zFVC being at least as great as those across quartiles of 
body mass index or systolic blood pressure.
dIscussIon
Principal findings
A broadly coherent picture emerges from this compar-
ison of UK national cohorts. Ventilatory function, even 
if measured imperfectly, consistently predicted both 
respiratory deaths and non-respiratory mortality from 
a range of causes. This was found even among lifelong 
non-smokers, so confounding by the amount or duration 
of active smoking is not the sole explanation. Both for 
all-cause mortality and more specifically for circulatory 
disease mortality, FEV1 and FVC were as strongly predic-
tive as body mass index and more strongly predictive than 
systolic blood pressure.
strengths and weaknesses of this study
UKB offers a spirometric study of lifelong non-smokers of 
unprecedented size, but its 5.5% participation rate may 
have compromised its generalisability. Assembling data 
from five UK national health surveys produced a cohort 
of never-smokers, larger than the combined number 
of participants in previous publications3,4 in which the 
generalisability of Biobank results could be tested. The 
similar pattern of results in HSE–SHS and UKB suggests 
that the key findings are generalisable, at least to the 
British population.
Within Biobank, the large numbers permitted subgroup 
analyses by sex, age, obesity and pre-existing disease, of 
sufficient statistical power to exclude important interac-
tion effects. These within-cohort comparisons provide 
further reassurance about the generalisability of the prin-
cipal findings among lifelong non-smokers.
Although only 58% of the Biobank cohort performed 
spirometry which fulfilled internationally recommended 
criteria for acceptability and reproducibility,17 the results 
in this subgroup were very similar to those among 
the full set of Biobank participants who performed 
‘usable’ spirometry. Those results were, in turn, consis-
tent with the findings from national health surveys where 
the acceptability and reproducibility of spirometry was 
not formally assessed in the field. These within-cohort 
and cross-cohort comparisons suggest that the principal 
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findings are robust to inclusion or exclusion of partici-
pants with suboptimal spirometric performance.
In common with previous studies of this topic, our 
analysis was restricted to fatal outcomes and therefore 
cannot distinguish between an influence of reduced 
ventilatory function on disease incidence and an effect 
on case fatality. The association with cancer mortality was 
weaker among those with no cancer diagnosis at entry, 
suggesting an association primarily with case fatality. 
In contrast, the association of spirometric indices with 
circulatory mortality was equally strong in those with 
and without a prior history of circulatory disease. The 
recent linkage of hospital admissions and primary care 
consultations to the UKB cohort will allow associations 
with incidence and case fatality to be investigated more 
directly in future.
comparison with other studies
Previous studies of lifelong non-smokers have been of 
limited size: 662 males and 2048 females in the Copen-
hagen City Heart Study, of whom 195 died during 10 years 
of follow-up,3 and 3562 male London civil servants in the 
Whitehall Study, of whom 408 died over a period of 18 
years.4 The Whitehall cohort was subsequently followed 
for 33–35 years, accumulating 1545 deaths among 3083 
lifelong non-smokers.19 In the analyses we present here, 
there are almost twice this number of deaths among life-
long non-smokers, despite a shorter follow-up period, 
due to the much larger sample size at entry, particularly 
in UKB.
The two publications from the Whitehall cohort4,19 
compared FEV1 and height as predictors of all-cause and 
cause-specific mortality among never-smokers. The first4 
found that FEV1 predicted mortality independent of 
height, but height did not predict survival independent 
of FEV1. The second19 found that FEV1 and height were 
similarly related both to mortality and to a range of other 
risk factors, concluding that both FEV1 and height may be 
markers of early life exposures of relevance to longevity.
Published analyses of the Whitehall cohort4,19 assessed 
only FEV1, but not FVC. In the Copenhagen study,3 the 
association of all-cause mortality among never-smokers 
was slightly stronger and more statistically significant 
with FVC than with FEV1 (both spirometric indices 
analysed as per cent predicted for age, sex and height). 
However, no formal comparison was made between the 
mortality risks associated with the two indices. An anal-
ysis of mortality over an average follow-up period of 13.7 
years among 7489 participants aged 45–64 years in the US 
ARIC cohort7 suggested that FVC should be considered as 
a more predictive spirometric index than FEV1, but this 
conclusion was drawn from a cohort of mixed smoking 
habits.
In our study of lifelong non-smokers, we confirmed that 
FVC (rather than FEV1) is the index of greater importance 
in determining survival in middle-aged never-smokers. 
In contrast, among current smokers, FEV1 emerged as 
the more influential predictor. This may be because the 
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Figure 1 Hazard ratios for death from all causes, and from circulatory diseases, by quartile of age–sex–height-adjusted zFVC, 
SBP and BMI among white lifelong non-smokers aged 40–69 years at entry in national health surveys (HSE and SHS) and in UK 
Biobank.  HRs are adjusted for age, sex, height, socioeconomic status, region and survey year. The reference category (HR=1) 
is the highest quartile (Q4) for zFVC and the lowest quartile (Q1) for SBP and BMI. Whiskers represent the 95% CI for each HR. 
Data included in online supplementary e-table 7. BMI, body mass index; FVC, forced vital capacity; HSE, Health Survey for 
England; SBP, systolic blood pressure; SHS, Scottish Health Survey; z, z-score.
FEV1:FVC ratio declines with both the dose and duration 
of smoking, and these also increase mortality risk.
The ability to perform good quality spirometry is an inte-
grated assessment of physical and cognitive function and 
therefore might be considered a predictor of mortality in 
its own right. In the US Six Cities Study, excessively vari-
able spirometric performance was an indicator of poor 
health and associated with shorter survival.20 In contrast, 
the mortality experience of Biobank participants who 
produced ‘best quality’ spirograms did not differ greatly 
from that of their peers who produced “'usable’ ‘but not’ 
‘best quality’ blows.
Possible implications
In clinical practice, particularly in primary care, quality 
control of spirometry is unlikely to be much better than 
in the national health surveys where lung function was 
tested by a trained research nurse in the home setting. 
Therefore, while the results from the Biobank ‘best 
quality’ subgroup are of confirmatory interest, the more 
inclusive results for all ‘usable spirograms’ may be more 
generally relevant.
In both cohorts, age–sex–height-adjusted lung function 
emerged as a stronger predictor of all-cause mortality 
than either systolic blood pressure or body mass index, 
which are, respectively, the second and sixth most influ-
ential causes worldwide of loss of healthy lifespan, as 
measured by disability-adjusted life years.21 It is therefore 
puzzling to find U-shaped or J-shaped relationships of 
mortality with these two cardiovascular risk factors, but 
the similar patterns of results in Biobank and the national 
health surveys suggest that this is not a unique feature of 
either of these British cohorts.
Specifically for circulatory disease mortality, FEV1 and 
FVC were as strongly predictive as body mass index and 
more strongly predictive than systolic blood pressure. 
Therefore, spirometry may deserve consideration as an 
addition to cardiovascular risk scoring algorithms in 
future.
conclusIon
More generally, these results emphasise the potential 
importance of promoting and protecting lung health in 
the general population, even among lifelong non-smokers 
with no history of respiratory disease.
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